Antisense-oligonucleotide mediated exon skipping in activin-receptor-like kinase 2: inhibiting the receptor that is overactive in fibrodysplasia ossificans progressiva

scientific article

Antisense-oligonucleotide mediated exon skipping in activin-receptor-like kinase 2: inhibiting the receptor that is overactive in fibrodysplasia ossificans progressiva is …
instance of (P31):
scholarly articleQ13442814

External links are
P819ADS bibcode2013PLoSO...869096S
P356DOI10.1371/JOURNAL.PONE.0069096
P932PMC publication ID3701692
P698PubMed publication ID23861958
P5875ResearchGate publication ID249967833

P50authorPeter A.C. 't HoenQ57190543
Dwi U KemaladewiQ59692180
Annemieke Aartsma-RusQ42215747
P2093author name stringPeter ten Dijke
Jie Cai
David J J de Gorter
Gonzalo Sanchez-Duffhues
Songting Shi
Willem M H Hoogaars
P2860cites workA recurrent mutation in the BMP type I receptor ACVR1 causes inherited and sporadic fibrodysplasia ossificans progressivaQ24321505
BMP-2/4 and BMP-6/7 differentially utilize cell surface receptors to induce osteoblastic differentiation of human bone marrow-derived mesenchymal stem cellsQ24328930
BMP type I receptor inhibition reduces heterotopic [corrected] ossificationQ24611307
Antisense-mediated exon skipping: a versatile tool with therapeutic and research applicationsQ24682555
Overactive bone morphogenetic protein signaling in heterotopic ossification and Duchenne muscular dystrophyQ26864900
Characterization of bone morphogenetic protein-6 signaling pathways in osteoblast differentiationQ28145299
ALK2 R206H mutation linked to fibrodysplasia ossificans progressiva confers constitutive activity to the BMP type I receptor and sensitizes mesenchymal cells to BMP-induced osteoblast differentiation and bone formationQ28265302
Abnormal angiogenesis but intact hematopoietic potential in TGF-beta type I receptor-deficient miceQ28361871
Lack of the bone morphogenetic protein BMP6 induces massive iron overloadQ28510138
Dorsomorphin inhibits BMP signals required for embryogenesis and iron metabolismQ29617479
Classic and atypical fibrodysplasia ossificans progressiva (FOP) phenotypes are caused by mutations in the bone morphogenetic protein (BMP) type I receptor ACVR1Q30373949
Identification of progenitor cells that contribute to heterotopic skeletogenesisQ30436925
Molecular consequences of the ACVR1(R206H) mutation of fibrodysplasia ossificans progressiva.Q33991272
Systemic administration of PRO051 in Duchenne's muscular dystrophyQ34172661
Conversion of vascular endothelial cells into multipotent stem-like cellsQ35532554
BMP2 activity, although dispensable for bone formation, is required for the initiation of fracture healing.Q52002102
BMP2 is required for early heart development during a distinct time period.Q52170375
Targeted exon skipping as a potential gene correction therapy for Duchenne muscular dystrophy.Q52547202
Deregulated bone morphogenetic protein receptor signaling underlies fibrodysplasia ossificans progressiva.Q54508841
BMP-9-induced muscle heterotopic ossification requires changes to the skeletal muscle microenvironment.Q54587581
Local dystrophin restoration with antisense oligonucleotide PRO051Q80412961
Bone morphogenetic protein-2 converts the differentiation pathway of C2C12 myoblasts into the osteoblast lineageQ36235105
An Acvr1 R206H knock-in mouse has fibrodysplasia ossificans progressivaQ36566730
Fibrodysplasia ossificans progressivaQ37105402
Splice modulating therapies for human diseaseQ37994280
BMP signaling in vascular diseasesQ38019702
Renal uptake of an 18-mer phosphorothioate oligonucleotideQ38290811
Exonic sequences provide better targets for antisense oligonucleotides than splice site sequences in the modulation of Duchenne muscular dystrophy splicingQ38345010
Guidelines for antisense oligonucleotide design and insight into splice-modulating mechanismsQ38360555
In vitro analyses of the dysregulated R206H ALK2 kinase-FKBP12 interaction associated with heterotopic ossification in FOP.Q38542691
Disease-causing allele-specific silencing against the ALK2 mutants, R206H and G356D, in fibrodysplasia ossificans progressivaQ39255284
Biphasic effects of transforming growth factor β on bone morphogenetic protein-induced osteoblast differentiationQ39536713
BMP antagonists enhance myogenic differentiation and ameliorate the dystrophic phenotype in a DMD mouse modelQ39645240
Murine endothelial cell lines as models of tumor endothelial cellsQ40574091
Exposure of KS483 cells to estrogen enhances osteogenesis and inhibits adipogenesisQ40746983
Subcloning of three osteoblastic cell lines with distinct differentiation phenotypes from the mouse osteoblastic cell line KS-4.Q41154242
Restoration of normal BMP signaling levels and osteogenic differentiation in FOP mesenchymal progenitor cells by mutant allele-specific targetingQ41994816
Comparative analysis of antisense oligonucleotide analogs for targeted DMD exon 46 skipping in muscle cellsQ44960581
Bone morphogenetic protein (BMP) type II receptor is required for BMP-mediated growth arrest and differentiation in pulmonary artery smooth muscle cellsQ46879441
P275copyright licenseCreative Commons Attribution 4.0 InternationalQ20007257
P6216copyright statuscopyrightedQ50423863
P433issue7
P407language of work or nameEnglishQ1860
P921main subjectfibrodysplasia ossificans progressivaQ1410831
P304page(s)e69096
P577publication date2013-07-04
P1433published inPLOS OneQ564954
P1476titleAntisense-oligonucleotide mediated exon skipping in activin-receptor-like kinase 2: inhibiting the receptor that is overactive in fibrodysplasia ossificans progressiva
P478volume8

Reverse relations

cites work (P2860)
Q38184276Antisense-mediated exon skipping: taking advantage of a trick from Mother Nature to treat rare genetic diseases
Q34512444Bone Morphogenetic Protein (BMP) signaling in development and human diseases
Q33587847Identification and characterization of regulatory elements in the promoter of ACVR1, the gene mutated in Fibrodysplasia Ossificans Progressiva.
Q34502398Molecular, phenotypic aspects and therapeutic horizons of rare genetic bone disorders
Q33635469Nonsense-mediated decay as a terminating mechanism for antisense oligonucleotides
Q58725014Recent Topics in Fibrodysplasia Ossificans Progressiva
Q38639065Shared ACVR1 mutations in FOP and DIPG: Opportunities and challenges in extending biological and clinical implications across rare diseases
Q35110776Targeted excision of VCP R155H mutation by Cre-LoxP technology as a promising therapeutic strategy for valosin-containing protein disease
Q92738367Targeting heterotopic ossification by inhibiting activin receptor‑like kinase 2 function (Review)
Q52340220The Horizon of a Therapy for Rare Genetic Diseases: A "Druggable" Future for Fibrodysplasia Ossificans Progressiva.
Q26752839The biological function of type I receptors of bone morphogenetic protein in bone
Q92152712The role of Activin A in fibrodysplasia ossificans progressiva: a prominent mediator
Q42370380Towards a cure for Fibrodysplasia ossificans progressiva.

Search more.